Among patients with aggressive prostate cancer, there is a high survival rate of those who undergo surgery, reports a new study.
The study is one of the first to focus exclusively on the outcomes after treatment for patients with high-risk prostate cancer.
Collaborating researchers at Mayo Clinic and Fox Chase Cancer Center in Philadelphia discovered that patients with the most aggressive forms of prostate cancer who had radical prostatectomy procedures had a 10-year cancer-specific survival rate of 92 percent and an overall survival rate of 77 percent.
"It's long been believed that patients with aggressive prostate cancer are not candidates for surgery. We found that surgery does provide excellent long-term cancer control for this type of prostate cancer. In addition, by allowing the targeted use of secondary therapies such as androgen deprivation, surgery offers the opportunity to avoid or at least delay the potentially adverse health consequences of these treatments," said Dr. Stephen Boorjian, a Mayo Clinic urologist.
Of the 1,847 patients with aggressive prostate cancer (as defined by the National Comprehensive Cancer Network) included in the study from 1988 to 2004, 1,238 underwent surgery at Mayo Clinic and 609 were treated with radiation therapy at Fox Chase Cancer Center.
Of the 609 receiving radiation therapy, 344 also received androgen deprivation therapy.
Researchers analysed their cancer-specific and overall survival rates.
The cancer-specific survival rate was equal for those who had surgery and those treated with radiation plus hormone therapy (92 percent).
However, the overall survival rate was significantly better for those who had the surgery (77 percent) than those who had radiation plus hormones (67 percent) or those who had radiation alone (52 percent).
"Patients with radiation and hormone therapy were 50 percent more likely to die than patients who had surgery. This was true even after controlling for patient age, comorbidities and features of the tumors. These results suggest that use of hormone therapy in patients who received radiation therapy may have had adverse health consequences," said Boorjian.
"We want to stress that surgery provides excellent long-term control for high-risk prostate cancer patients. Limiting the need for hormones may avoid adverse health consequences. Further studies evaluating the differing impacts of treatments on quality of life and non-cancer mortality are necessary before we can determine the best approach for patients with aggressive prostate cancer," he added.
The findings were presented at the North Central Section of the American Urological Association's 84th Annual Meeting held in Chicago.